Solid Biosciences Inc.
SLDB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001707502
No open-market purchases or sales by Solid Biosciences Inc. insiders were filed in the last 90 days; 157 institutions reported holding it in 13F filings for Q2 2026, worth $1.14B in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +10 vs. previous quarter
- 157
- 13F valueReported value at the end of Q2 2026
- $1.14B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding SLDB, Q2 2026
No superinvestor reported holding SLDB at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Solid Biosciences Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 18, 2026 (view filing) | Feb 18 | Same day | Cumbo AlexanderPresident and CEO | SSale | −16.6K | $5.82 | −$96.9K | −6.6%235.4K after | 10b5-1 |
| Feb 18, 2026 (view filing) | Feb 18 | Same day | Hanrahan JessieChief Regulatory Officer | SSale | −4.13K | $5.82 | −$24.1K | −5.3%74.3K after | 10b5-1 |
| Feb 18, 2026 (view filing) | Feb 18 | Same day | Ganot IlanDirector | SSale | −2.66K | $5.82 | −$15.5K | −8.8%27.5K after | 10b5-1 |
| Feb 18, 2026 (view filing) | Feb 18 | Same day | Herzich PaulChief Technology Officer | SSale | −3.62K | $5.82 | −$21.0K | −4.7%72.6K after | 10b5-1 |
| Feb 18, 2026 (view filing) | Feb 18 | Same day | Howton David TChief Operating Officer | SSale | −7.47K | $5.82 | −$43.5K | −6.6%105.1K after | 10b5-1 |
| Feb 18, 2026 (view filing) | Feb 18 | Same day | Brooks GabrielChief Medical Officer | SSale | 0 | – | $0 | 0.0%89.5K after | 10b5-1 |
| Feb 18, 2026 (view filing) | Feb 18 | Same day | Tan KevinCFO & Treasurer | SSale | −5.40K | $5.82 | −$31.5K | −5.2%99.4K after | 10b5-1 |
| Feb 6, 2026 (view filing) | Feb 4 | 2 days | Howton David TChief Operating Officer | SSale | −18.9K | $6.44 | −$121.7K | −16.2%97.9K after | 10b5-1 |
| Feb 6, 2026 (view filing) | Feb 4 | 2 days | Cumbo AlexanderPresident and CEO | SSale | −48.9K | $6.44 | −$315.0K | −18.1%222.0K after | 10b5-1 |
| Feb 6, 2026 (view filing) | Feb 4 | 2 days | Ganot IlanDirector | SSale | −7.21K | $6.44 | −$46.4K | −22.2%25.3K after | 10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Solid Biosciences Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 12,036,126 | $120.2M | 1.04% | +2,696,148+28.9% | Added |
| Perceptive Advisors LLC | 11,906,646 | $118.9M | 1.85% | 00.0% | Unchanged |
| Bain Capital Life Sciences Investors, LLC | 9,808,819 | $98.0M | 5.83% | 00.0% | Unchanged |
| Siren, L.L.C. | 7,690,405 | $76.8M | 1.56% | 00.0% | Unchanged |
| BlackRock, Inc. | 6,934,248 | $69.3M | 0.00% | +1,975,894+39.8% | Added |
| FMR LLC | 6,875,957 | $68.7M | 0.00% | +3,269,553+90.7% | Added |
| Armistice Capital, LLC | 4,278,000 | $42.7M | 1.18% | +1,078,000+33.7% | Added |
| State Street Corp | 4,175,365 | $41.7M | 0.00% | +3,049,878+271.0% | Added |
| Jupiter Topco LLC | 4,043,605 | $40.4M | 0.02% | +4,043,605 | New |
| Vanguard Capital Management LLC | 4,009,922 | $40.1M | 0.00% | +1,335,298+49.9% | Added |